更正 -- 维泰瑞隆宣布委任王舒展先生为董事会董事

Core Insights - Vitarion, a clinical-stage biotechnology company, focuses on developing transformative therapies for neurodegenerative diseases, inflammatory immune diseases, metabolic diseases, and rare diseases [1][3] - The company announced the appointment of Wang Shuzhan, Managing Director of Yunfeng Fund, to its board, highlighting his extensive experience in investment and operational leadership in the life sciences sector [1][2] - Vitarion has a diverse pipeline of projects targeting key pathogenic mechanisms related to aging, degenerative changes, metabolic dysfunction, and inflammation, with ongoing clinical studies for several candidates [3] Group 1 - Vitarion is dedicated to developing innovative therapies for various diseases, including neurodegenerative and rare diseases [1][3] - The company has established a robust scientific foundation and an exciting R&D pipeline since its inception in 2017 [3] - Wang Shuzhan's addition to the board is expected to complement the existing board's expertise and support the clinical development of first-in-class or best-in-class innovations [1][2] Group 2 - The company is currently conducting clinical research on multiple projects, including SARM1 inhibitor SIR2501, NAMPT agonist SIR4156, and RIPK1 inhibitor SIR9900, while also advancing preclinical studies [3] - Vitarion was recognized in the 2025 Endpoints 11 list of the most promising biotechnology startups, indicating its potential in the industry [3]